Post by Amylyx Pharmaceuticals

75,416 followers

Amylyx is presenting two posters at the Endocrine Society’s Annual Meeting, #ENDO2026. We look forward to sharing insights on the burden of PBH in the U.S. on healthcare resource utilization, economic impact, and quality of life, as well as participant-centric trial design considerations for our pivotal Phase 3 LUCIDITY clinical trial. See presentation details below and in today’s release: https://bit.ly/43q7AKv

Post content

Video Content